Capital Fund Management S.A. reduced its holdings in shares of C.R. Bard, Inc. (NYSE:BCR) by 63.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,491 shares of the medical instruments supplier’s stock after selling 28,974 shares during the quarter. Capital Fund Management S.A.’s holdings in C.R. Bard were worth $5,213,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of C.R. Bard by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 7,881,464 shares of the medical instruments supplier’s stock valued at $1,958,858,000 after buying an additional 205,186 shares during the last quarter. BlackRock Inc. boosted its stake in shares of C.R. Bard by 1,365.7% during the 1st quarter. BlackRock Inc. now owns 7,398,081 shares of the medical instruments supplier’s stock valued at $1,838,719,000 after buying an additional 6,893,346 shares during the last quarter. State Street Corp boosted its stake in shares of C.R. Bard by 3.5% during the 1st quarter. State Street Corp now owns 3,831,621 shares of the medical instruments supplier’s stock valued at $952,313,000 after buying an additional 128,045 shares during the last quarter. Fundsmith LLP boosted its stake in shares of C.R. Bard by 2.1% during the 1st quarter. Fundsmith LLP now owns 2,553,141 shares of the medical instruments supplier’s stock valued at $633,996,000 after buying an additional 52,272 shares during the last quarter. Finally, FMR LLC boosted its stake in shares of C.R. Bard by 4.2% during the 1st quarter. FMR LLC now owns 986,276 shares of the medical instruments supplier’s stock valued at $245,129,000 after buying an additional 39,817 shares during the last quarter. Institutional investors own 79.34% of the company’s stock.

Shares of C.R. Bard, Inc. (NYSE:BCR) opened at 323.73 on Tuesday. C.R. Bard, Inc. has a 12 month low of $203.63 and a 12 month high of $324.58. The firm has a market capitalization of $23.53 billion, a price-to-earnings ratio of 42.50 and a beta of 0.60. The firm has a 50-day moving average price of $320.16 and a 200 day moving average price of $295.78.

C.R. Bard (NYSE:BCR) last announced its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.84 by $0.08. C.R. Bard had a return on equity of 48.70% and a net margin of 14.99%. The business had revenue of $979.70 million for the quarter, compared to analyst estimates of $976.53 million. During the same quarter in the previous year, the firm earned $2.54 EPS. C.R. Bard’s quarterly revenue was up 5.2% on a year-over-year basis. On average, analysts anticipate that C.R. Bard, Inc. will post $11.84 EPS for the current fiscal year.

In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of C.R. Bard stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $318.73, for a total value of $7,549,757.51. Following the completion of the transaction, the insider now owns 31,445 shares in the company, valued at approximately $10,022,464.85. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.80% of the company’s stock.

BCR has been the subject of several research analyst reports. Zacks Investment Research upgraded C.R. Bard from a “hold” rating to a “buy” rating and set a $360.00 target price for the company in a research note on Monday, July 31st. Jefferies Group LLC reiterated a “hold” rating on shares of C.R. Bard in a research note on Thursday, August 3rd. BidaskClub lowered C.R. Bard from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Finally, BMO Capital Markets reissued a “hold” rating and set a $317.00 price target on shares of C.R. Bard in a research report on Tuesday, July 11th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $285.67.

ILLEGAL ACTIVITY WARNING: “C.R. Bard, Inc. (BCR) Shares Sold by Capital Fund Management S.A.” was reported by Daily Political and is the property of of Daily Political. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://www.dailypolitical.com/2017/09/12/c-r-bard-inc-bcr-shares-sold-by-capital-fund-management-s-a.html.

C.R. Bard Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.